Literature DB >> 22284892

Autologous stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients.

S Kirana1, B Stratmann, C Prante, W Prohaska, H Koerperich, D Lammers, M H Gastens, T Quast, M Negrean, O A Stirban, S G Nandrean, C Götting, P Minartz, K Kleesiek, D Tschoepe.   

Abstract

BACKGROUND AND AIM: Despite improvements in surgical revascularisation, limitations like anatomical factors or atherosclerosis limit the success of revascularisation in diabetic patients with critical limb ischaemia. Stem cells were shown to improve microcirculation in published studies. The aim of this study was to evaluate safety, feasibility and efficacy of transplantation of bone marrow derived cellular products regarding improvement in microcirculation and lowering of amputation rate.
METHODS: Bone marrow mononuclear cells (BMCs) in comparison with expanded bone marrow cells enriched in CD90+ cells ('tissue repair cells', TRCs) were used in the treatment of diabetic ulcers to induce revascularisation. Diabetic foot patients with critical limb ischaemia without option for surgical or interventional revascularisation were eligible. Parameters examined were ABI, TcPO(2) , reactive hyperaemia and angiographic imaging before and after therapy.
RESULTS: Of 30 patients included in this trial, 24 were randomised to receive either BMCs or TRCs. The high number of drop-outs in the control group (4 of 6) led to exclusion from evaluation. A total of 22 patients entered treatment; one patient in the TRC group and two in the BMC group did not show wound healing during follow up, one patient in each treatment group died before reaching the end of the study; one after having achieved wound healing (BMC group), the other one without having achieved wound healing (TRC group). Thus, 18 patients showed wound healing after 45 weeks. The total number of applicated cells was 3.8 times lower in the TRC group, but TRC patients received significantly higher amounts of CD90+ cells. Improvement in microvascularisation was detected in some, but not all patients by angiography, TcPO(2) improved significantly compared with baseline in both therapy groups.
CONCLUSION: The transplantation of BMCs as well as TRCs proved to be safe and feasible. Improvements of microcirculation and complete wound healing were observed in the transplant groups.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22284892     DOI: 10.1111/j.1742-1241.2011.02886.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  44 in total

Review 1.  Modulating the vascular response to limb ischemia: angiogenic and cell therapies.

Authors:  John P Cooke; Douglas W Losordo
Journal:  Circ Res       Date:  2015-04-24       Impact factor: 17.367

Review 2.  The current state of stem cell therapy for peripheral artery disease.

Authors:  Nitin K Gupta; Ehrin J Armstrong; Sahil A Parikh
Journal:  Curr Cardiol Rep       Date:  2014-02       Impact factor: 2.931

3.  Efficacy, safety and influencing factors of intra-calf muscular injection of bone marrow mononuclear cells in the treatment of type 2 diabetes mellitus-induced lower extremity vascular disease.

Authors:  Hui-Min Zhou; Fan Liu; Ai-Ge Yang; Yu-Qing Guo; Ya-Ru Zhou; Yong-Quan Gu; Bao-Yong Yan; Quan-Hai Li
Journal:  Exp Ther Med       Date:  2017-09-22       Impact factor: 2.447

4.  Evaluation of persistence and distribution of intra-dermally administered PKH26 labelled goat bone marrow derived mesenchymal stem cells in cutaneous wound healing model.

Authors:  M D Pratheesh; Nitin E Gade; Amar Nath; Pawan K Dubey; T B Sivanarayanan; D N Madhu; T R Sreekumar; G Saikumar; G Taru Sharma
Journal:  Cytotechnology       Date:  2017-05-11       Impact factor: 2.058

Review 5.  Growth factors for angiogenesis in peripheral arterial disease.

Authors:  Vitali Gorenoi; Michael U Brehm; Armin Koch; Anja Hagen
Journal:  Cochrane Database Syst Rev       Date:  2017-06-08

6.  Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients.

Authors:  S Fadilah Abdul Wahid; Nor Azimah Ismail; Wan Fariza Wan Jamaludin; Nor Asiah Muhamad; Muhammad Khairul Azaham Abdul Hamid; Hanafiah Harunarashid; Nai Ming Lai
Journal:  Cochrane Database Syst Rev       Date:  2018-08-29

Review 7.  Activity of mesenchymal stem cells in therapies for chronic skin wound healing.

Authors:  Austin Nuschke
Journal:  Organogenesis       Date:  2013-12-10       Impact factor: 2.500

8.  Regression modeling to inform cell incorporation into therapies for craniosynostosis.

Authors:  James Cray; Gregory M Cooper
Journal:  J Craniofac Surg       Date:  2013-01       Impact factor: 1.046

9.  Transplantation of Human Placenta-Derived Mesenchymal Stem Cells Alleviates Critical Limb Ischemia in Diabetic Nude Rats.

Authors:  Lu Liang; Zongjin Li; Tao Ma; Zhibo Han; Wenjing Du; Jie Geng; Honghong Jia; Meng Zhao; Jimin Wang; Bingjing Zhang; Jie Feng; Lanzhen Zhao; Alain Rupin; Youwei Wang; Zhong Chao Han
Journal:  Cell Transplant       Date:  2016-08-05       Impact factor: 4.064

10.  Impaired T-cell differentiation in diabetic foot ulceration.

Authors:  João Moura; João Rodrigues; Marta Gonçalves; Cláudia Amaral; Margarida Lima; Eugénia Carvalho
Journal:  Cell Mol Immunol       Date:  2016-03-21       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.